Obermatt
See Similar Stocks →

Flags

Financial distress

Bausch Health Companies

TOR:BHC · CA0717341071
PharmaceuticalsX-Large

360

21
EV / EBIT90
Price / Owner Earnings68
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit85
Price/Book86
Return on Capital75
Cash Return on Capital31
EBIT Margin80
Gross Profitability51
Accruals81
Owner Earnings Margin21
Sales growth45
Profit Growth91
Long-Term EPS Growth37
Owner Earnings Growth9
Reinvestment22
Price momentum49
Debt load10
Refinancing100
Debt Payback1
Liquidity66
Analyst ratings9
Opinion Changes50
Price Target Upside46
Market mood19
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Bausch Health Companies clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryCanada
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNYSE
Employees2,384
Websitebauschhealth.com
ISINCA0717341071
Last UpdateApr 2, 2026
Indices
TSX Composite (Canada)
Themes
OphthalmologyNeurologyDermatologyGastroenterologyDentistryBiotechnologyHealth CareManufacturingMedical DevicePharmaceutical

Description

Bausch Health Companies Inc. operates as a specialty pharmaceutical and medical device company worldwide. The company develops, manufactures, and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermato…

Analysis

Middle-of-the-road

Bausch Health Companies Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is fragile. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: A large part of the company's book value is the price paid for past acquisitions. Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
72
2023202420252026

All-time high

72

Jun 2026

All-time low

14

Jul 2023

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
95
95
84
Price/Earnings
41
96
100
100
Price/Book
86
96
95
98
Dividend Yield
1
1
1
1
Value (overall)
94
98
100
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bausch Health Companies with its peers
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aquestive Therapeutics
NMQ:AQST
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ANI Pharma
NMQ:ANIP
98
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Vericel
NMQ:VCEL
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Amphastar Pharmaceuticals
NSQ:AMPH
63
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →